Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norwich Eaton's Didronel (etidronate)

Executive Summary

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Didronel's use in treating postmenopausal osteoporosis on March 8. The meeting is currently scheduled to be held at FDA's Parklawn building in conference rooms D & E. The NDA was filed in July 1990. Didronel tablets are currently indicated for treating Paget's disease and heterotopic ossification following total hip replacement or spinal cord injury. Didronel I.V. is indicated for treating hypercalcemia of malignancy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel